Overview

Optimal Administration of Allopurinol in Dialysis Patients

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some evidence shows that it is also dialyzable. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication.
Phase:
Phase 4
Details
Lead Sponsor:
Maisonneuve-Rosemont Hospital
Treatments:
Allopurinol